572 related articles for article (PubMed ID: 23380337)
41. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Gordon DB
Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
[TBL] [Abstract][Full Text] [Related]
42. Single-dose fentanyl sublingual spray for breakthrough cancer pain.
Taylor DR
Clin Pharmacol; 2013; 5():131-41. PubMed ID: 23901300
[TBL] [Abstract][Full Text] [Related]
43. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
[TBL] [Abstract][Full Text] [Related]
44. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
45. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
46. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Giuliani J; Fiorica F; Sacchetto A; Franceschini G; Vaccari F; Bonetti A
J Oncol Pharm Pract; 2021 Mar; 27(2):445-447. PubMed ID: 33356990
[TBL] [Abstract][Full Text] [Related]
47. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain.
Passik SD; Messina J; Golsorkhi A; Xie F
J Pain Symptom Manage; 2011 Jan; 41(1):116-25. PubMed ID: 20580202
[TBL] [Abstract][Full Text] [Related]
48. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
Mercadante S
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
[TBL] [Abstract][Full Text] [Related]
49. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
Mercadante S
Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
[TBL] [Abstract][Full Text] [Related]
51. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Hanks GW; Nugent M; Higgs CM; Busch MA;
Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
[TBL] [Abstract][Full Text] [Related]
52. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.
Lichtor JL; Sevarino FB; Joshi GP; Busch MA; Nordbrock E; Ginsberg B
Anesth Analg; 1999 Sep; 89(3):732-8. PubMed ID: 10475315
[TBL] [Abstract][Full Text] [Related]
53. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Nalamachu S; Hassman D; Wallace MS; Dumble S; Derrick R; Howell J
Curr Med Res Opin; 2011 Mar; 27(3):519-30. PubMed ID: 21208151
[TBL] [Abstract][Full Text] [Related]
54. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
56. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain.
Bhatnagar S; Devi S; Vinod N; Jain P; Durgaprasad G; Maroo SH; Patel KR
Indian J Palliat Care; 2014 Sep; 20(3):182-7. PubMed ID: 25191003
[TBL] [Abstract][Full Text] [Related]
58. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
59. Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
Lecybyl R; Hanna M
Future Oncol; 2007 Aug; 3(4):375-9. PubMed ID: 17661711
[TBL] [Abstract][Full Text] [Related]
60. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
